New findings regarding diabetes risk in childhood cancer survivors
Four previously unknown genetic variants provide a new understanding of differences in risk between individuals of varying ancestries.
List view / Grid view
Four previously unknown genetic variants provide a new understanding of differences in risk between individuals of varying ancestries.
The pharmacological inhibition of class IIa HDACs could be a therapeutic approach for addressing Th17-related inflammatory and autoimmune diseases.
In this article, Dr Robert Scoffin, Chairman and CEO at Cresset, explores FEP and its current challenges, and outlines how continuous advancements and strategic approaches are helping to drive the adoption of FEP methods in drug discovery.
In mouse models, the differences between oocytes collected by natural or stimulated approaches were investigated.
It was discovered that targeting RAS proteins prevent cancer cells from using different signalling pathways to escape cell death.
Researchers find the mechanism which may underly the onset and progression of age-related neurodegenerative diseases.
In this Q&A, Léo Marx, Medicinal Chemistry Project Manager at Debiopharm, details how the therapeutic window of ADCs can be impacted, how we can overcome the challenges associated with achieving site-specific bioconjugation, and other essential considerations for optimising ADC performance.
The new study found T3s treatment exhibited neuroprotective effects in HFSD-fed mice by mitigating oxidative stress.
Researchers have identified that gestational diabetes is associated with a deficit in placental expression of IGFBP1.
The new findings could result in a clinical trial to assess whether a one-year course of treatment could stop brain tumours.
Although pre-targeting is still in its infancy, it has immense potential to increase state-of-the-art radioligand therapies. In this Q&A, PreTT reveals how their pre-targeted RLTs surpass traditional methods, transforming cancer treatment.
The discovery of three m6A modifications and their exact locations could lead to the development of drugs that inhibit viral RNA and protein production.
Elevated levels of trimethylamine N-oxide levels were a stronger indicator of CKD risk than the well-known risk factors.
In this Q&A, Associate Professor Dr Mete Civelek shares insights from the University of Virginia’s exciting recent study identifying several potential therapeutic targets for accelerating translational research in cardiovascular disease treatment, with a focus on proteins associated with the extracellular matrix (ECM) secretion by smooth muscle cells (SMCs).
Using cortical organoids, researchers discovered that targeting KCNJ2 could reduce nerve cell death after TBI.